SangStat Bets on Focus vs. Size
Executive Summary
Up against Novartis, the Swiss marketing giant that now owns the $1.3 billion market for cyclosporine, SangStat insists that its disease management approach to organ transplantation is the right model at the right time.
You may also be interested in...
Facing the Challenges in Transplantation
The transplantation market has changed considerably since Novartis (via its predecessor, Sandoz) launched the then-revolutionary selective immunosuppressant cyclosporin in 1983. Nowadays, clinicians and patients have many more treatment options--thanks largely to enhanced understanding of immunology--and thus the trend is strongly towards individualized therapy. In response to this shift, Novartis has given up pursuing radically new approaches to treatment and is concentrating on developing a product for every class of drug now used to treat graft recipients.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.